Medscape November 10, 2023
The first vaccine for chikungunya, an emerging mosquito-borne global health threat marked by fever and joint pain, has been granted accelerated approval by the US Food and Drug Administration (FDA).
The vaccine, called Ixchiq, was granted fast-track and breakthrough-therapy designations in June, and the application has now received a priority review designation.
The risk for chikungunya infection is highest in the tropical and subtropical regions of Africa, Southeast Asia, and parts of the Americas, where chikungunya virus-carrying mosquitos are endemic, according to the FDA. However, the chikungunya virus has been spreading geographically, increasing its global prevalence.
At least 5 million cases have been reported globally in the past 15 years, the agency reported yesterday.
The new vaccine is approved for...
Today's Sponsors
Today's Sponsor